These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
632 related articles for article (PubMed ID: 29583083)
21. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Bone HG; Wagman RB; Brandi ML; Brown JP; Chapurlat R; Cummings SR; Czerwiński E; Fahrleitner-Pammer A; Kendler DL; Lippuner K; Reginster JY; Roux C; Malouf J; Bradley MN; Daizadeh NS; Wang A; Dakin P; Pannacciulli N; Dempster DW; Papapoulos S Lancet Diabetes Endocrinol; 2017 Jul; 5(7):513-523. PubMed ID: 28546097 [TBL] [Abstract][Full Text] [Related]
22. What is the best balance of benefits and risks among anti-resorptive therapies for postmenopausal osteoporosis? Miller PD; Derman RJ Osteoporos Int; 2010 Nov; 21(11):1793-802. PubMed ID: 20309524 [TBL] [Abstract][Full Text] [Related]
23. Safety of denosumab in postmenopausal women with osteoporosis or low bone mineral density: a meta-analysis. Zhou Z; Chen C; Zhang J; Ji X; Liu L; Zhang G; Cao X; Wang P Int J Clin Exp Pathol; 2014; 7(5):2113-22. PubMed ID: 24966919 [TBL] [Abstract][Full Text] [Related]
24. How to manage postmenopausal osteoporosis? Body JJ Acta Clin Belg; 2011; 66(6):443-7. PubMed ID: 22338309 [TBL] [Abstract][Full Text] [Related]
25. Denosumab compared to other treatments to prevent or treat osteoporosis in individuals at risk of fracture: a systematic review and meta-analysis. Beaudoin C; Jean S; Bessette L; Ste-Marie LG; Moore L; Brown JP Osteoporos Int; 2016 Sep; 27(9):2835-2844. PubMed ID: 27120345 [TBL] [Abstract][Full Text] [Related]
26. Denosumab versus Bisphosphonates for Reducing Fractures in Postmenopausal Women with Osteoporosis: A Meta-Analysis. Thal KA; Nudy M; Moser EM; Foy AJ J Am Board Fam Med; 2023 Feb; 36(1):175-185. PubMed ID: 36653115 [TBL] [Abstract][Full Text] [Related]
30. Osteoporosis, bone mineral density and CKD-MBD: treatment considerations. Bover J; Bailone L; López-Báez V; Benito S; Ciceri P; Galassi A; Cozzolino M J Nephrol; 2017 Oct; 30(5):677-687. PubMed ID: 28432640 [TBL] [Abstract][Full Text] [Related]
31. Denosumab or oral bisphosphonates in primary osteoporosis: a "real-life" study. Cairoli E; Palmieri S; Goggi G; Roggero L; Arosio M; Chiodini I; Eller-Vainicher C J Endocrinol Invest; 2018 Aug; 41(8):1005-1013. PubMed ID: 29340971 [TBL] [Abstract][Full Text] [Related]
32. Observations following discontinuation of long-term denosumab therapy. McClung MR; Wagman RB; Miller PD; Wang A; Lewiecki EM Osteoporos Int; 2017 May; 28(5):1723-1732. PubMed ID: 28144701 [TBL] [Abstract][Full Text] [Related]
33. Persistence at 24 months with denosumab among postmenopausal women with osteoporosis: results of a prospective cohort study. Silverman SL; Siris E; Belazi D; Recknor C; Papaioannou A; Brown JP; Gold DT; Lewiecki EM; Quinn G; Balasubramanian A; Yue S; Stolshek B; Kendler DL Arch Osteoporos; 2018 Aug; 13(1):85. PubMed ID: 30088189 [TBL] [Abstract][Full Text] [Related]
34. Denosumab mid-term densitometric gain in postmenopausal osteoporosis women in clinical practice: comment on "Variability of denosumab densitometric response in postmenopausal osteoporosis". Torrente-Segarra V; Roig-Vilaseca D Rheumatol Int; 2018 Jun; 38(6):1161-1162. PubMed ID: 29546636 [TBL] [Abstract][Full Text] [Related]
35. Response to Therapy With Teriparatide, Denosumab, or Both in Postmenopausal Women in the DATA (Denosumab and Teriparatide Administration) Study Randomized Controlled Trial. Leder BZ; Tsai JN; Neer RM; Uihlein AV; Wallace PM; Burnett-Bowie SA J Clin Densitom; 2016; 19(3):346-51. PubMed ID: 26900146 [TBL] [Abstract][Full Text] [Related]
36. A model of fracture risk used to examine the link between bone mineral density and the impact of different therapeutic mechanisms on fracture outcomes in patients with osteoporosis. Eudy-Byrne RJ; Gillespie W; Riggs MM; Gastonguay MR J Pharmacokinet Pharmacodyn; 2017 Dec; 44(6):599-609. PubMed ID: 29081020 [TBL] [Abstract][Full Text] [Related]
37. Importance of prompt antiresorptive therapy in postmenopausal women discontinuing teriparatide or denosumab: The Denosumab and Teriparatide Follow-up study (DATA-Follow-up). Leder BZ; Tsai JN; Jiang LA; Lee H Bone; 2017 May; 98():54-58. PubMed ID: 28286299 [TBL] [Abstract][Full Text] [Related]
39. The safety and tolerability profile of therapies for the prevention and treatment of osteoporosis in postmenopausal women. Komm BS; Morgenstern D; A Yamamoto L; Jenkins SN Expert Rev Clin Pharmacol; 2015; 8(6):769-84. PubMed ID: 26482902 [TBL] [Abstract][Full Text] [Related]
40. Bone Loss After Denosumab: Only Partial Protection with Zoledronate. Reid IR; Horne AM; Mihov B; Gamble GD Calcif Tissue Int; 2017 Oct; 101(4):371-374. PubMed ID: 28500448 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]